Novavax completes U.S. marketing authorization transfer to Sanofi for Nuvaxovid, earns $25M milestone

NOVAVAX INC

FDA approved transfer of U.S. marketing authorization for Nuvaxovid from Novavax to Sanofi on Nov 3, 2025.
Second $25M milestone payment triggered; follows EU transfer in Oct 2025. Payment expected Q1 2026.
Total non-dilutive capital secured YTD 2025 from Sanofi milestones is $225M.
Sanofi now responsible for U.S. commercial and regulatory activities for Nuvaxovid.
CEO John C. Jacobs notes delivery on partnership obligations and future royalties.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.